February 24, 2020 Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report
January 29, 2020 ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project. The ERA4TB (European Regimen Ac
December 13, 2019 Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials
December 5, 2019 Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease to Inform Clinical Trial Designs Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit...
December 2, 2019 Workshop Summary, Advancing the Development and Implementation of Analysis Data Standards, Now Available C-Path is proud to announce the availability of the workshop summary, Advancing the Development and Implementation of Analysis Dat
October 29, 2019 U.S. Senator Martha McSally Visits C-Path U.S. Senator Martha McSally (Arizona) visited Tucson-based Critical Path Institute (C-Path) Friday, October 25, to learn more abou
October 22, 2019 Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data
October 21, 2019 Towards EMA Qualification of Islet Auto-Antibodies as a Model-Based Clinical Trial Enrichment Platform for Type-1 Diabetes Prevention Studies
October 15, 2019 C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies TUCSON, Ariz. and AUSTIN, Texas, October 15, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announc
